Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Caterina Alati et al.|The Lancet Haematology|2017Cited by 163
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeMaria Antonietta Aloe Spiriti, Maria Concetta Petti, Roberto Latagliata et al.|Annals of Hematology|2004Cited by 110
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther Natalie Olíva, Maria Antonietta Aloe Spiriti, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 30
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Luciano Masini, Raffaella Marcheselli et al.|Leukemia & lymphoma/Leukemia and lymphoma|2011Cited by 28
Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre studyPellegrino Musto, Alessandro Levis, Luca Maurillo et al.|British Journal of Haematology|2017Cited by 25